241 related articles for article (PubMed ID: 33580969)
41. ALK-positive histiocytosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: a multitarget response under ibrutinib.
Syrykh C; Ysebaert L; Péricart S; Evrard SM; Meggetto F; Kanoun S; Brousset P; Laurent C
Virchows Arch; 2021 Apr; 478(4):779-783. PubMed ID: 33011863
[TBL] [Abstract][Full Text] [Related]
42. [Current diagnosis and treatment of chronic lymphocytic leukaemia].
Cramer P; von Tresckow J; Eichhorst B; Hallek M
Dtsch Med Wochenschr; 2020 Aug; 145(16):1139-1144. PubMed ID: 32791549
[TBL] [Abstract][Full Text] [Related]
43. Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model.
Ahn IE; Tian X; Ipe D; Cheng M; Albitar M; Tsao LC; Zhang L; Ma W; Herman SEM; Gaglione EM; Soto S; Dean JP; Wiestner A
J Clin Oncol; 2021 Feb; 39(6):576-585. PubMed ID: 33026937
[TBL] [Abstract][Full Text] [Related]
44. Ibrutinib for Chronic Lymphocytic Leukemia with
Ahn IE; Tian X; Wiestner A
N Engl J Med; 2020 Jul; 383(5):498-500. PubMed ID: 32726539
[No Abstract] [Full Text] [Related]
45. Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study.
Kabadi SM; Near A; Wada K; Burudpakdee C
Adv Ther; 2020 Jul; 37(7):3129-3148. PubMed ID: 32399812
[TBL] [Abstract][Full Text] [Related]
46. Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.
Innocenti I; Sora F; Autore F; Chiusolo P; Giammarco S; Metafuni E; Bacigalupo A; Sica S; Laurenti L
Hematol Oncol; 2021 Apr; 39(2):267-269. PubMed ID: 33150962
[No Abstract] [Full Text] [Related]
47. Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study.
Rigolin GM; Del Giudice I; Bardi A; Melandri A; García-Jacobo RE; Cura F; Raponi S; Ilari C; Cafforio L; Piciocchi A; Arena V; Reda G; Albano F; Molica S; Sportoletti P; Trentin L; Marchetti M; Nanni M; Peragine N; Mariglia P; Vignetti M; Guarini A; Mauro FR; Foà R; Cuneo A
Blood; 2021 Dec; 138(25):2727-2730. PubMed ID: 34587233
[No Abstract] [Full Text] [Related]
48. The impacts of zanubrutinib on immune cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
Zou YX; Zhu HY; Li XT; Xia Y; Miao KR; Zhao SS; Wu YJ; Wang L; Xu W; Li JY
Hematol Oncol; 2019 Oct; 37(4):392-400. PubMed ID: 31420873
[TBL] [Abstract][Full Text] [Related]
49. Long-term Efficacy of Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of the Polish Adult Leukemia Study Group Observational Study.
Pula B; Iskierka-Jazdzewska E; Dlugosz-Danecka M; Szymczyk A; Hus M; Szeremet A; Drozd-Sokolowska J; Waszczuk-Gajda A; Zaucha JM; Holojda J; Piszczek W; Steckiewicz P; Wojciechowska M; Osowiecki M; Knopinska-Posluszny W; Dudzinski M; Zawirska D; Subocz E; Halka J; Pluta A; Wichary R; Kumiega B; Budziszewska BK; Jurczak W; Lech-Maranda E; Giannopoulos K; Robak T; Jamroziak K
Anticancer Res; 2020 Jul; 40(7):4059-4066. PubMed ID: 32620653
[TBL] [Abstract][Full Text] [Related]
50. Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients.
Miller CR; Huang Y; Ruppert AS; Labanowska J; Jaglowski SM; Maddocks KJ; Rogers KA; Bhat S; Kittai AS; Grever M; Lapalombella R; Abruzzo LV; Heerema NA; Byrd JC; Hertlein EK; Woyach JA
Leukemia; 2021 Nov; 35(11):3287-3290. PubMed ID: 33820961
[No Abstract] [Full Text] [Related]
51. Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study.
Bomben R; Rossi FM; Vit F; Bittolo T; Zucchetto A; Papotti R; Tissino E; Pozzo F; Degan M; Polesel J; Bulian P; Marasca R; Reda G; Laurenti L; Olivieri J; Chiarenza A; Laureana R; Postorino M; Del Principe MI; Cuneo A; Gentile M; Morabito F; Fronza G; Tafuri A; Zaja F; Foà R; Di Raimondo F; Del Poeta G; Gattei V
Leukemia; 2023 Apr; 37(4):914-918. PubMed ID: 36807650
[No Abstract] [Full Text] [Related]
52. Effects of CD20 antibodies and kinase inhibitors on B-cell receptor signalling and survival of chronic lymphocytic leukaemia cells.
Cavallini C; Galasso M; Pozza ED; Chignola R; Lovato O; Dando I; Romanelli MG; Krampera M; Pizzolo G; Donadelli M; Scupoli MT
Br J Haematol; 2021 Jan; 192(2):333-342. PubMed ID: 33216963
[TBL] [Abstract][Full Text] [Related]
53. Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL.
Killock D
Nat Rev Clin Oncol; 2023 Feb; 20(2):64. PubMed ID: 36543933
[No Abstract] [Full Text] [Related]
54. Chronic lymphocytic leukaemia-associated insect bite-like reaction responding to ibrutinib, an immunomodulatory Bruton tyrosine kinase inhibitor.
Wimalachandra M; Basu TN; Salisbury J; Attard N; Calonje E; Patten PEM
Clin Exp Dermatol; 2021 Dec; 46(8):1569-1571. PubMed ID: 34028865
[No Abstract] [Full Text] [Related]
55. Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia.
Huang Q; Emond B; Lafeuille MH; Gupta D; Lefebvre P; Sundaram M; Mato A
Curr Med Res Opin; 2020 Dec; 36(12):2009-2018. PubMed ID: 33044848
[TBL] [Abstract][Full Text] [Related]
56. Similar efficacy of ibrutinib arms across ALPINE and ELEVATE-RR trials in relapsed/refractory chronic lymphocytic leukemia: a matching-adjusted indirect comparison.
Shadman M; Tedeschi A; Mohseninejad L; Yang K; Lamanna N; Xu S; Cohen A; Challagulla S; Xue M; Williams R; O'Brien SM; Brown JR; Tam C
Blood Cancer J; 2024 May; 14(1):77. PubMed ID: 38697986
[No Abstract] [Full Text] [Related]
57. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
[TBL] [Abstract][Full Text] [Related]
58. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
[TBL] [Abstract][Full Text] [Related]
59. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia.
Patel KK; Isufi I; Kothari S; Davidoff AJ; Gross CP; Huntington SF
Blood; 2020 Oct; 136(17):1946-1955. PubMed ID: 32518952
[TBL] [Abstract][Full Text] [Related]
60. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
